Other Income and Expense Items

12 Months Ended

Jun. 30, 2025

Other Income and Expense Items [Abstract]

Other income and expense items

3 Other income and expense items

(a) Other income

	30 June 2025 $		30 June 2024 $		30 June 2023 $
Interest		888,196		50,484		145,035
Research and Development tax incentive		9,368,544		1,292,578		5,917,484
		10,256,740		1,343,062		6,062,519

(i) R&D tax incentive

The group’s research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Where expenditure is incurred outside of Australia, an ‘overseas finding’ must be obtained from AusIndustry prior to any such expenditure being eligible under the scheme. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2025, the group has included an item in other income of $9,368,544 (2024: $1,292,578, 2023: $5,917,484) to recognize income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate. The assistance received is a direct cash payment from the ATO and is not related to any tax liability or income tax calculation.

The $1,292,578 recognized at 30 June 2024 includes $489,590 relating to the prior years rebate. The funds were only received in the prior year and eligibility to receive the rebate for this expenditure was less than certain prior to this as the overseas findings for program was not received until the prior year. The $9,368,544 recognized at 30 June 2025 includes $3,587,887 relating to prior years rebate. The funds were only received in the current year and eligibility to receive the rebate for this expenditure was less than certain prior to this as the overseas findings for program was not received until the current year. For the year ended 30 June 2023, the group has included an item in other income of $5,917,484 to recognize income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate. The $5,917,484 recognized at 30 June 2023 includes $1,555,235 relating to the prior years rebate.

(b) Other losses

	Notes	30 June 2025 $			30 June 2024 $			30 June              2023                   $
Fair value adjustment on financing agreements			(489,787	)		366,719			-
Net foreign exchange gains/(losses)			138,141			94,964			(257,251	)
Loss on sale of available-for-sale assets	6(a)		-			(1,687,791	)		-
			(351,646	)		(1,226,108	)		(257,251	)

(c) Breakdown of expenses by nature

	Notes	30 June 2025 $		30 June 2024 $		30 June 2023 $
General and administrative expenses
Accounting and audit			957,895		845,818		1,205,015
Consulting			286,138		95,179		1,117,981
Depreciation			7,331		7,534		6,553
Employee benefits			10,120,149		9,448,779		6,149,314
Insurance			105,762		359,209		685,413
Investor relations			313,671		323,588		565,032
Legal			656,036		164,754		959,258
Listing and share registry			190,795		193,797		164,116
Patent costs			205,017		204,163		205,709
Travel and entertainment			808,546		427,676		648,532
Other			986,673		968,749		524,125
			14,638,013		13,039,246		12,231,048
Research and development
Amortization			2,588,306		3,118,752		3,289,979
AVb6 Integrin (TRIMT)			1,876,983		993,645		3,735,540
Consulting Fees R&D			930,292		929,229		2,441,106
hu PSA Anti-body (Diaprost)			2,925,445		298,312		1,571,795
Impairment	6(b)(viii)		-		1,478,892		3,100,000
R&D Ventures			5,989,964		3,931,541		324,888
NanoMab			7,185,000		6,501,174		6,090,209
Neoindicate			437,400		529,424		538,906
Pharma15			-		-		10,724
Pivalate - Imperial			5,184,136		3,962,355		1,195,120
UCLA			226,063		1,253,493		333,242
Other			171,605		89,450		-
			27,515,194		23,086,267		22,631,509

The categories shown here align with the intellectual property held by the group as disclosed in note 6 and represents the amount of R&D expended on developing the respective intellectual property.